Launch Therapeutics Selects Medidata AI Intelligent Trials
Partnership optimizes trial planning and efficiency.
Medidata has announced that Launch Therapeutics (Launch Tx) selected Medidata AI Intelligent Trials to support its approach to accelerating clinical trials of late-stage therapies.
Medidata AI Intelligent Trials’ Study Feasibility solution provides Launch Tx with higher assurance that trial planning will improve enrollment and quality. This is done by leveraging country and site-level performance data, and predictive analytics. It’s built on a foundation of data from more than 30,000 clinical trials across a wide array of disease indications representing more than nine million study participants.
Reference
Launch Therapeutics Selects Medidata AI Intelligent Trials to Accelerate Clinical Trial Development. (2023, April 12). Medidata.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
